Market Cap 492.13M
Revenue (ttm) 292.50M
Net Income (ttm) -33.99M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -11.62%
Debt to Equity Ratio 0.00
Volume 1,227,200
Avg Vol 415,654
Day's Range N/A - N/A
Shares Out 41.22M
Stochastic %K 1%
Beta 0.43
Analysts Strong Sell
Price Target $19.33

Company Profile

AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company's thrombus management portfolio includes AlphaVac mechanical thrombectomy sy...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 518 795 1400
Address:
14 Plaza Drive, Latham, United States
JMJTrading
JMJTrading Apr. 2 at 1:55 PM
$AYI over $300 this week, Earnings beat for 23 er in a row! $RGC $ANGO
0 · Reply
JMJTrading
JMJTrading Apr. 2 at 12:53 PM
$AYI nice ER, lets see $300 break! $ANGO $LNN $VCX @DavidScott @topstockalerts
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Apr. 2 at 11:38 AM
$ANGO Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.19 down -72.73% YoY • Reported revenue of $78.42M up 8.91% YoY • AngioDynamics raised its full year FY 2026 guidance for net sales to $313.5M and Adjusted EBITDA to $10M. AngioDynamics expects Med Tech net sales growth of 15%-17% and anticipates slightly negative cash flow for FY26 due to inventory build.
0 · Reply
MorganHoratio
MorganHoratio Apr. 2 at 11:08 AM
BREAKING: AngioDynamics ($ANGO) just dropped its FQ3 FY2026 results — and the trend is loud and clear. DOUBLE-DIGIT growth in MedTech continues to power the engine Profitability sustained despite macro headwinds Momentum building in core segments while the company sharpens its focus on higher-margin innovation This isn’t just a quarterly beat — it’s a signal. Execution + growth + profitability = a setup traders can’t ignore. Watch for volume expansion and follow-through. When fundamentals align like this, moves can accelerate FAST. Is $ANGO setting up for the next leg higher… or just getting started?
0 · Reply
backtesttrend
backtesttrend Apr. 2 at 10:24 AM
💉 $ANGO Reports Q3 FY2026 results Sustained double-digit growth in med tech Continues profitability trend
0 · Reply
Estimize
Estimize Apr. 2 at 10:00 AM
$ANGO reported - EPS and - revenue for Q3. http://www.estimize.com/intro/ango?chart=historical&metric_name=eps&utm_content=ANGO&utm_medium=
0 · Reply
TradeTracs
TradeTracs Apr. 2 at 4:50 AM
Three pre-market earnings dropping Thursday AM — here's what matters 👀 $LNN at $117.15, below all key MAs, RSI 35.20 — already oversold heading into print. Down 11.94% last month on 1.95x volume. This one's fragile. $AYI at $286.98, RSI 53.79, battling back toward SMA 50 at $295.31 — down 21% QTD so expectations are reset. $ANGO ripping +5% pre-earnings, trading above all three MAs on 1.54x volume. RSI 65.43 — momentum is real but fading into the number is the risk. Watchlist: $LNN bounce or breakdown at $106 support. $AYI needs a beat to reclaim $295. $ANGO — don't chase. #Earnings #StockMarket #Trading
0 · Reply
JMJTrading
JMJTrading Apr. 1 at 9:47 PM
$AYI tomorrow morning is ER - Very bullish here - AYI has beaten earnings estimates for 22 consecutive quarters, 22, with an average surprise of 8% over the last year! Estimates: Consensus EPS is $4.11 on $1.09 billion in revenue, representing a 10.2% year-over-year earnings increase. Analyst have a "Moderate Buy" with an average price target of $380.17, that is 32% potential here. $ANGO $LNN $VCX
0 · Reply
isaac92173
isaac92173 Apr. 1 at 8:15 PM
$ANGO what is the news yall?
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 27 at 12:03 AM
$ANGO Share Price: $11.27 Contract Selected: Oct 16, 2026 $10 Calls Buy Zone: $1.70 – $2.10 Target Zone: $2.73 – $3.34 Potential Upside: 52% ROI Time to Expiration: 203 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Latest News on ANGO
AngioDynamics, Inc. (ANGO) Q3 2026 Earnings Call Transcript

Apr 2, 2026, 10:12 AM EDT - 1 day ago

AngioDynamics, Inc. (ANGO) Q3 2026 Earnings Call Transcript


AngioDynamics, Inc. (ANGO) Q2 2026 Earnings Call Transcript

Jan 6, 2026, 10:18 AM EST - 3 months ago

AngioDynamics, Inc. (ANGO) Q2 2026 Earnings Call Transcript


AngioDynamics: Growth Remains Under The Radar

Dec 29, 2025, 6:47 PM EST - 3 months ago

AngioDynamics: Growth Remains Under The Radar


AngioDynamics, Inc. (ANGO) Q1 2026 Earnings Call Transcript

Oct 2, 2025, 10:02 AM EDT - 6 months ago

AngioDynamics, Inc. (ANGO) Q1 2026 Earnings Call Transcript


Nasdaq Surges 100 Points; AngioDynamics Posts Upbeat Q1 Results

Oct 2, 2025, 9:44 AM EDT - 6 months ago

Nasdaq Surges 100 Points; AngioDynamics Posts Upbeat Q1 Results


AngioDynamics, Inc. (ANGO) Q4 2025 Earnings Call Transcript

Jul 15, 2025, 12:40 PM EDT - 9 months ago

AngioDynamics, Inc. (ANGO) Q4 2025 Earnings Call Transcript


AngioDynamics, Inc. (ANGO) Q3 2025 Earnings Call Transcript

Apr 2, 2025, 10:20 AM EDT - 1 year ago

AngioDynamics, Inc. (ANGO) Q3 2025 Earnings Call Transcript


AngioDynamics to Host Virtual Cardiovascular Investor Event

Mar 31, 2025, 8:00 AM EDT - 1 year ago

AngioDynamics to Host Virtual Cardiovascular Investor Event


AngioDynamics: A Surgical Approach To Market Growth

Jan 8, 2025, 5:15 PM EST - 1 year ago

AngioDynamics: A Surgical Approach To Market Growth


AngioDynamics, Inc. (ANGO) Q2 2025 Earnings Call Transcript

Jan 8, 2025, 11:00 AM EST - 1 year ago

AngioDynamics, Inc. (ANGO) Q2 2025 Earnings Call Transcript


JMJTrading
JMJTrading Apr. 2 at 1:55 PM
$AYI over $300 this week, Earnings beat for 23 er in a row! $RGC $ANGO
0 · Reply
JMJTrading
JMJTrading Apr. 2 at 12:53 PM
$AYI nice ER, lets see $300 break! $ANGO $LNN $VCX @DavidScott @topstockalerts
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Apr. 2 at 11:38 AM
$ANGO Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.19 down -72.73% YoY • Reported revenue of $78.42M up 8.91% YoY • AngioDynamics raised its full year FY 2026 guidance for net sales to $313.5M and Adjusted EBITDA to $10M. AngioDynamics expects Med Tech net sales growth of 15%-17% and anticipates slightly negative cash flow for FY26 due to inventory build.
0 · Reply
MorganHoratio
MorganHoratio Apr. 2 at 11:08 AM
BREAKING: AngioDynamics ($ANGO) just dropped its FQ3 FY2026 results — and the trend is loud and clear. DOUBLE-DIGIT growth in MedTech continues to power the engine Profitability sustained despite macro headwinds Momentum building in core segments while the company sharpens its focus on higher-margin innovation This isn’t just a quarterly beat — it’s a signal. Execution + growth + profitability = a setup traders can’t ignore. Watch for volume expansion and follow-through. When fundamentals align like this, moves can accelerate FAST. Is $ANGO setting up for the next leg higher… or just getting started?
0 · Reply
backtesttrend
backtesttrend Apr. 2 at 10:24 AM
💉 $ANGO Reports Q3 FY2026 results Sustained double-digit growth in med tech Continues profitability trend
0 · Reply
Estimize
Estimize Apr. 2 at 10:00 AM
$ANGO reported - EPS and - revenue for Q3. http://www.estimize.com/intro/ango?chart=historical&metric_name=eps&utm_content=ANGO&utm_medium=
0 · Reply
TradeTracs
TradeTracs Apr. 2 at 4:50 AM
Three pre-market earnings dropping Thursday AM — here's what matters 👀 $LNN at $117.15, below all key MAs, RSI 35.20 — already oversold heading into print. Down 11.94% last month on 1.95x volume. This one's fragile. $AYI at $286.98, RSI 53.79, battling back toward SMA 50 at $295.31 — down 21% QTD so expectations are reset. $ANGO ripping +5% pre-earnings, trading above all three MAs on 1.54x volume. RSI 65.43 — momentum is real but fading into the number is the risk. Watchlist: $LNN bounce or breakdown at $106 support. $AYI needs a beat to reclaim $295. $ANGO — don't chase. #Earnings #StockMarket #Trading
0 · Reply
JMJTrading
JMJTrading Apr. 1 at 9:47 PM
$AYI tomorrow morning is ER - Very bullish here - AYI has beaten earnings estimates for 22 consecutive quarters, 22, with an average surprise of 8% over the last year! Estimates: Consensus EPS is $4.11 on $1.09 billion in revenue, representing a 10.2% year-over-year earnings increase. Analyst have a "Moderate Buy" with an average price target of $380.17, that is 32% potential here. $ANGO $LNN $VCX
0 · Reply
isaac92173
isaac92173 Apr. 1 at 8:15 PM
$ANGO what is the news yall?
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 27 at 12:03 AM
$ANGO Share Price: $11.27 Contract Selected: Oct 16, 2026 $10 Calls Buy Zone: $1.70 – $2.10 Target Zone: $2.73 – $3.34 Potential Upside: 52% ROI Time to Expiration: 203 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 25 at 3:46 AM
$ANGO RSI: 41.67, MACD: -0.1281 Vol: 0.33, MA20: 10.89, MA50: 10.74 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Estimize
Estimize Mar. 23 at 1:21 PM
Wall St is expecting -0.11 EPS for $ANGO Q3 [Reporting 04/02 BMO] http://www.estimize.com/intro/ango?chart=historical&metric_name=eps&utm_c
0 · Reply
SwingPlay
SwingPlay Mar. 18 at 6:51 PM
$ANGO breaking fucking $315 and we shall see $310 and $300 again.
0 · Reply
ZacksResearch
ZacksResearch Mar. 11 at 4:43 PM
Why $ANGO's growth story is just beginning! 🚀 With $ANGO's NanoKnife seeing revenue jump 22.2% YoY, driven by prostate cancer procedure adoption. Plus, the Auryon franchise reported its 18th straight quarter of double-digit growth in the second quarter. Discover why ANGO could continue to outperform 👉 https://www.zacks.com/stock/news/2882503/reasons-to-add-angiodynamics-stock-to-your-portfolio-for-now?cid=sm-stocktwits-2-2882503-body-37022&ADID=SYND_STOCKTWITS_TWEET_2_2882503_BODY_37022
0 · Reply
ZacksResearch
ZacksResearch Mar. 11 at 3:43 PM
$ANGO is gaining serious momentum — and the story might just be getting started. 👀 Strong fiscal Q2 results, surging NanoKnife adoption in prostate cancer, and broad Med Tech growth are all helping support margins and strengthen the investment case. See why ANGO could deserve a spot in your portfolio 👉 https://www.zacks.com/stock/news/2882503/reasons-to-add-angiodynamics-stock-to-your-portfolio-for-now?cid=sm-stocktwits-2-2882503-teaser-37012&ADID=SYND_STOCKTWITS_TWEET_2_2882503_TEASER_37012
0 · Reply
Estimize
Estimize Mar. 11 at 10:03 AM
Wall St is expecting -0.11 EPS for $ANGO Q3 [Reporting 04/02 BMO] http://www.estimize.com/intro/ango?chart=historical&metric_name=eps&utm_c
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 4 at 12:51 PM
$ANGO RSI: 50.52, MACD: 0.0938 Vol: 0.38, MA20: 11.05, MA50: 11.26 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
ZacksResearch
ZacksResearch Feb. 23 at 6:14 PM
$ANGO just widened its oncology footprint in Europe — and that’s a big deal. AngioDynamics expanded NanoKnife’s EU indications to include liver, pancreas, kidney and prostate tumors, significantly broadening its reach and growth runway in multi-organ tumor ablation. That’s meaningful expansion, not incremental progress. Could this unlock the next leg of growth? Get the full breakdown 👉 https://www.zacks.com/stock/news/2873809/ango-expands-nanoknife-in-europe-for-multi-organ-tumor-ablation?cid=sm-stocktwits-2-2873809-teaser-34767&ADID=SYND_STOCKTWITS_TWEET_2_2873809_TEASER_34767
0 · Reply
ZacksResearch
ZacksResearch Feb. 23 at 5:14 PM
$ANGO gains on expanded NanoKnife approval in Europe! 🚀 Broader approvals for liver, pancreas, kidney, and prostate tumors open up significant market potential, reinforcing NanoKnife as a versatile oncology platform. 📈 With Europe contributing to 28% of global IRE volumes, ANGO is set for growth. Discover the full story here 👉 https://www.zacks.com/stock/news/2873809/ango-expands-nanoknife-in-europe-for-multi-organ-tumor-ablation?cid=sm-stocktwits-2-2873809-body-34751&ADID=SYND_STOCKTWITS_TWEET_2_2873809_BODY_34751
0 · Reply
TheWolfOfSanFran
TheWolfOfSanFran Feb. 23 at 2:50 AM
$ANGO m&A target possibly. 👀
0 · Reply
Estimize
Estimize Feb. 19 at 11:24 PM
Wall St is expecting -0.11 EPS for $ANGO Q3 [Reporting 04/02 BMO] http://www.estimize.com/intro/ango?chart=historical&metric_name=eps&utm_c
0 · Reply
OpenOutcrier
OpenOutcrier Feb. 19 at 2:01 PM
$ANGO (+2.4% pre) AngioDynamics gains European approval for NanoKnife tumor treatment https://ooc.bz/l/93907
0 · Reply